A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

241 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-10-22

Study Completion Date

2033-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, side effects, and efficacy of LY4337713. In addition, this study will evaluate how much LY4337713 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For each participant, the study will last about 5 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Neoplasms Breast Neoplasms Pancreatic Intraductal Neoplasms Colorectal Neoplasms Esophageal Neoplasms Stomach Neoplasms Cholangiocarcinoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cancer-associated fibroblasts (CAF) Lutetium-177 LuFAP Lu-177-FAP

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY4337713 (Cohort A1)

Escalating doses of LY4337713 administered intravenously (IV).

Group Type EXPERIMENTAL

LY4337713

Intervention Type DRUG

Administered IV.

LY4337713 (Cohort A2)

Two or more dose regimens of LY4337713 (evaluated during dose escalation) administered IV.

Group Type EXPERIMENTAL

LY4337713

Intervention Type DRUG

Administered IV.

Experimental: LY4337713 (Cohort B)

Tumor specific cohort will receive LY4337713 administered IV.

Group Type EXPERIMENTAL

LY4337713

Intervention Type DRUG

Administered IV.

Experimental LY4337713 (Cohort C)

Tumor specific cohort will receive LY4337713 administered IV.

Group Type EXPERIMENTAL

LY4337713

Intervention Type DRUG

Administered IV.

Experimental: LY4337713 (Cohort D)

Tumor specific cohort will receive LY4337713 administered IV.

Group Type EXPERIMENTAL

LY4337713

Intervention Type DRUG

Administered IV.

LY4337713 (Cohort E)

Tumor specific cohort will receive LY4337713 administered IV.

Group Type EXPERIMENTAL

LY4337713

Intervention Type DRUG

Administered IV.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY4337713

Administered IV.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment
* Must have histologically or cytologically confirmed diagnosis of one of the following:

* Adenocarcinoma of the pancreas
* Hormone receptor (HR)-positive human epidermal growth factor 2 (HER2)-negative breast cancer
* HER2-positive breast cancer
* Triple negative breast cancer (TNBC)
* Platinum-resistant or refractory ovarian cancer
* Other solid tumors

* Gastric cancer (adenocarcinoma)
* Colorectal cancer (CRC)
* Esophageal cancer (squamous cell carcinoma or adenocarcinoma)
* Cholangiocarcinoma
* Must have received prior treatments as indicated below:

* Phase 1a

* Adenocarcinoma of the pancreas: Participants must have progressed after at least 1, but no more than 2 prior regimens for locally advanced unresectable or metastatic disease.
* HR-positive HER2-negative breast cancer: Participants must have received less than or equal to (≤)5 prior lines of treatment for advanced or metastatic disease, which must include a cyclin-dependent kinase 4/6 inhibitor.
* HER2-positive breast cancer: Participants must have progressed on at least 2 lines of HER2-targeted therapy, which should include at least 1 antibody-drug conjugate (ADC) for metastatic disease (if locally available).
* TNBC: Participants must have progressed on at least 2 lines of therapy for metastatic disease.
* Platinum-resistant or refractory ovarian cancer: Participants must have progressed on or after at least 1 platinum-based therapy.
* Other solid tumors (gastric cancer, CRC, esophageal and cholangiocarcinoma): Participants must have received greater than or equal to (≥)1 prior line of systemic therapy for advanced or metastatic disease; including prior line(s) in combination with immunotherapy or vascular endothelial growth factor inhibitor.
* Phase 1b:

* Participants must have advanced or metastatic solid tumors and have received ≥1 prior line of therapy.
* Must have an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.
* Measured creatinine clearance ≥60 milliliters per minute (mL/min)

Exclusion Criteria

* Have known active central nervous system (CNS) metastases or carcinomatous meningitis.
* Have history of Grade 4 myelosuppression lasting greater than (\>)7 days, or Grade 3 myelosuppression requiring more than 6 weeks recovery.
* Have significant cardiovascular disease
* Have prolongation of the corrected QTcF \>470 milliseconds (msec) during screening. QTcF is calculated using Fridericia's Formula: QTcF = QT/(RR0.33)
* Have evidence of ongoing and untreated urinary tract obstruction
* Had previous hemi- or total-body radiation.
* Had previous adoptive T-cell therapy (e.g., chimeric antigen receptor T-cell \[CAR-T therapy, T-cell receptor \[TCR\] therapy, etc.)
* Unable to lie flat during, or otherwise tolerate, single photon emission computed tomography (SPECT), positron emission tomography (PET), computed tomography (CT) or magnetic resonance imaging (MRI).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Site Status RECRUITING